Literature DB >> 16736247

TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease.

M M Edwards1, S R Robinson.   

Abstract

Neurodegenerative disorders such as Alzheimer's disease are characterized by increased intracellular and extracellular concentrations of the astrocytic proteins glial fibrillary acidic protein (GFAP) and S100B. The present study examined the potential contribution of tumor necrosis factor alpha (TNFalpha) to these changes by measuring astrocyte viability along with the intracellular and extracellular expression of GFAP and S100B following exposure to this cytokine. Although TNFalpha did not affect astrocyte viability, the extracellular levels of both proteins were increased three-fold with associated reductions in immunocytochemical labeling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16736247     DOI: 10.1007/s00702-006-0479-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  53 in total

1.  Increased S100 beta neurotrophic activity in Alzheimer's disease temporal lobe.

Authors:  D R Marshak; S A Pesce; L C Stanley; W S Griffin
Journal:  Neurobiol Aging       Date:  1992 Jan-Feb       Impact factor: 4.673

2.  Glial fibrillary acidic protein and beta A4 protein deposits in temporal lobe of aging brain and senile dementia of the Alzheimer type: relation with the cognitive state and with quantitative studies of senile plaques and neurofibrillary tangles.

Authors:  M L Harpin; P Delaère; F Javoy-Agid; E Bock; C Jacque; B Delpech; H Villarroya; C Duyckaerts; J J Hauw; N Baumann
Journal:  J Neurosci Res       Date:  1990-12       Impact factor: 4.164

Review 3.  The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease.

Authors:  R E Mrak; W S Griffinbc
Journal:  Neurobiol Aging       Date:  2001 Nov-Dec       Impact factor: 4.673

4.  Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia.

Authors:  A J Green; R J Harvey; E J Thompson; M N Rossor
Journal:  Neurosci Lett       Date:  1997-10-10       Impact factor: 3.046

5.  Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease.

Authors:  R E Mrak; J G Sheng; W S Griffin
Journal:  J Neuropathol Exp Neurol       Date:  1996-03       Impact factor: 3.685

6.  Increased permeability of primary cultured brain microvessel endothelial cell monolayers following TNF-alpha exposure.

Authors:  K S Mark; D W Miller
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

7.  Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease.

Authors:  E R Peskind; W S Griffin; K T Akama; M A Raskind; L J Van Eldik
Journal:  Neurochem Int       Date:  2001 Nov-Dec       Impact factor: 3.921

Review 8.  Cytokines in dementias.

Authors:  Elisabeth Tarkowski
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2002-06

9.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Authors:  W S Griffin; L C Stanley; C Ling; L White; V MacLeod; L J Perrot; C L White; C Araoz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

10.  Elevated circulating tumor necrosis factor levels in Alzheimer's disease.

Authors:  H Fillit; W H Ding; L Buee; J Kalman; L Altstiel; B Lawlor; G Wolf-Klein
Journal:  Neurosci Lett       Date:  1991-08-19       Impact factor: 3.046

View more
  26 in total

1.  Accumulation of non-transferrin-bound iron by neurons, astrocytes, and microglia.

Authors:  Glenda M Bishop; Theresa N Dang; Ralf Dringen; Stephen R Robinson
Journal:  Neurotox Res       Date:  2010-04-30       Impact factor: 3.911

2.  S100B Protein Regulates Astrocyte Shape and Migration via Interaction with Src Kinase: IMPLICATIONS FOR ASTROCYTE DEVELOPMENT, ACTIVATION, AND TUMOR GROWTH.

Authors:  Flora Brozzi; Cataldo Arcuri; Ileana Giambanco; Rosario Donato
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

3.  Cross-talk between neurons and astrocytes in response to bilirubin: adverse secondary impacts.

Authors:  Ana Sofia Falcão; Rui F M Silva; Ana Rita Vaz; Cátia Gomes; Adelaide Fernandes; Andreia Barateiro; Claudio Tiribelli; Dora Brites
Journal:  Neurotox Res       Date:  2014-07       Impact factor: 3.911

4.  S100B attenuates microglia activation in gliomas: possible role of STAT3 pathway.

Authors:  Leying Zhang; Wei Liu; Darya Alizadeh; Dongchang Zhao; Omar Farrukh; Jeffrey Lin; Sam A Badie; Behnam Badie
Journal:  Glia       Date:  2010-12-29       Impact factor: 7.452

5.  Uptake and Toxicity of Hemin and Iron in Cultured Mouse Astrocytes.

Authors:  Jessica E Owen; Glenda M Bishop; Stephen R Robinson
Journal:  Neurochem Res       Date:  2015-12-22       Impact factor: 3.996

6.  Treadmill training restores spatial cognitive deficits and neurochemical alterations in the hippocampus of rats submitted to an intracerebroventricular administration of streptozotocin.

Authors:  Letícia Rodrigues; Márcio Ferreira Dutra; Jocemar Ilha; Regina Biasibetti; André Quincozes-Santos; Marina C Leite; Simone Marcuzzo; Matilde Achaval; Carlos-Alberto Gonçalves
Journal:  J Neural Transm (Vienna)       Date:  2010-10-16       Impact factor: 3.575

Review 7.  Dual Functions of Microglia in Ischemic Stroke.

Authors:  Chuan Qin; Luo-Qi Zhou; Xiao-Tong Ma; Zi-Wei Hu; Sheng Yang; Man Chen; Dale B Bosco; Long-Jun Wu; Dai-Shi Tian
Journal:  Neurosci Bull       Date:  2019-05-06       Impact factor: 5.203

8.  The S100B/RAGE Axis in Alzheimer's Disease.

Authors:  Estelle Leclerc; Emmanuel Sturchler; Stefan W Vetter
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-06-21

9.  Cross-talk between neurons and astrocytes in response to bilirubin: early beneficial effects.

Authors:  Ana Sofia Falcão; Rui F M Silva; Ana Rita Vaz; Sandra Leitão Silva; Adelaide Fernandes; Dora Brites
Journal:  Neurochem Res       Date:  2013-01-03       Impact factor: 3.996

Review 10.  Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence.

Authors:  Edward Tobinick
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.